The findings have implications for scheduling repeat dosing in eligible children, the authors say.
Our systematic review published this week shows that rigorous, transparent evidence synthesis can persist even when traditional advisory processes falter.
The large-scale project was conducted by the Center for Infectious Disease Research and Policy's Vaccine Integrity Project.
The overall estimated RSV incidence in young children was about 3 times higher in ambulatory care than in emergency departments.
Adjusted effectiveness against emergency department visits/hospitalizations was 95% among patients aged 75 and older.
HEPA purifiers were associated with a 33% decrease in viral diversity, but the reduction wasn't linked to fewer school absences.
But there is 'substantial opportunity' for load-balancing strategies during future pediatric hospital surges to reduce bed strain and harm, the authors say.
The Vaccine Integrity Project staff and advisors note the conspicuous and consequential absence of US health agency vaccine campaigns and annual vaccination reminders ahead of respiratory virus season.
Data on the efficacy of RSV vaccines on women of childbearing age and on infants and children were more limited.
In other developments, the CDC reported one more pediatric flu death, raising the season's total to 281, the highest for a nonpandemic year.
